Premium Alternative Insight and Premium Journalism
Larry Robbins’s hedge fund could have fared worse given sharp declines in key holdings and bad timing with some winners.
The Latest
Several managed futures and trend-following funds are down sharply this year.
Most life sciences hedge funds, including Casdin Capital and Cormorant, are sinking deeper into the red.
While post-tariff returns aren’t in, D1, Viking, Lone Pine, and others outperformed the market in March and the first quarter.
The Discovery founder thinks there will be strong growth in the second half of the year.
Hedge funds that were once a big source of capital to venture are wary of new commitments despite the reset in company valuations since the peak in 2022.
Dan Loeb’s fund established the position in the car company in Q1 as the stock was peaking, according to filings.
“We doubled down at just getting better at what we do,” even as funds changed their short strategies and money went to multistrats, says Chris Hansen.
More in Premium
